Seeking Alpha

InVivo Therapeutics' (NVIV +18.6%) CEO tells shareholders the drug company's stock is...

InVivo Therapeutics' (NVIV +18.6%) CEO tells shareholders the drug company's stock is undervalued following a recent drop, and he expects the next six months to mark a "major inflection point" in growth. He expects FDA approval to start a study for the use of NVIV's biopolymer scaffolding to treat spinal cord injuries.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|